It took nearly 20 years for PROTAC technology to transform from academia to preclinical and clinical drug development projects. In 2019, PROTAC obtained the clinical proof of concept in oncology for theRead More…
The wide range of application and the great potential in overcoming drug resistance and targeting non-proprietary targets, research and development in PROTAC field has been hot in recent years. PROTAC, protein degradationRead More…
PROTACs, also named as Proteolysis-Targeting Chimeras, is a new type of drug that is different from antibodies and traditional small molecular inhibitors. It consists of target proteins ligand, linker, and E3 ubiquitinRead More…
Main steps of PROTAC to achieve intracellular protein degradation To achieve intracellular protein degradation requires multiple steps, such as cellular uptake, effective recruitment of E3 ligase, ubiquitination of target proteins, and recruitmentRead More…
In 2004, the Nobel Prize in Chemistry was awarded to Israeli scientists Aaron Sichanova, Afram Hershko and American scientist Irwin Ross for their discovery of ubiquitin-regulated protein degradation. Protein degradation is ratedRead More…
Advantages of PROTAC technology Through PROTAC technology, it is possible to develop drugs against undruggable or difficult-to-drug targets of traditional inhibitors. The PROTAC does not rely on the active site ofRead More…
On December 14, 2020, Arvinas, a pioneer of PROTAC, announced the results of phase I clinical trials of new PROTAC drugs ARV-471 and ARV-110, of which ARV-471 showed outstanding efficacy in patientsRead More…
On January 26th, the application for the clinical trial of HSK29116 powder declared by Sichuan Haisco Pharmaceutical Co., Ltd. was accepted by the State Food and Drug Administration. HSK29116 is an oralRead More…
PROTAC is a novel technique that induces targeted protein degradation by the ubiquitin-proteasome system (UPS). Different from the traditional occupation-driven pharmacological principles, event-driven PROTAC technology has many advantages, such as high activity,Read More…
On December 14, 2020, Arvinas released the latest clinical data of ARV-471 and ARV-110, which showed strong therapeutic potential. As soon as the news was released, Arvinas’s share price doubled, with aRead More…